If you have a patient that is showing symptoms or complaining about Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD), we may be able to help them. We offer free pre-screen evaluations to determine inclusion criteria for a research trial, and provide additional resources and referrals to help you in your treatment plans for your patients. We are a Clinical Trial Center wholly funded by pharmaceutical companies and other agencies that fund our trials.
Please contact us to refer a patient
Neuropsychiatric Research Center of Southwest Florida
An ERG Portfolio Company
14271 Metropolis Ave., Suite A
Fort Myers, FL 33912
- In 2001, the late Frederick W. Schaerf, M.D., Ph.D. founded the Neuropsychiatric Research Center of Southwest Florida, which has become a globally recognized clinical research site, specializing in Alzheimer's disease and related memory disorders. Dr. Schaerf conducted over 200 clinical trials dedicated to dementia.
- Patients will continue to receive the latest diagnostic and treatments available in a safe, well controlled environment.
- Melissa Schaerf, M.S., A.R.N.P. is the Site Director and Sub-Investigator. She has been Dr. Schaerf's partner and director since the research centers inception. She has been involved in clinical research for over twenty years. Melissa is continuing the work in our region and provides accurate and up-to-date information.
- Wendy Bond, M.D., Principal Investigator, is Board Certified by the American Board of Psychiatry and Neurology with years of experience specializing in Alzheimer's disease. As the P.I., she will provide accurate and up-to-date information.
- Jennifer Springer, M.D., Sub-Investigator, has resided in Southwest Florida for years and worked part-time in the Health Park Emergency Department and at Lee Convenient Care. As a Sub-P.I., she will provide accurate and up-to-date information.
- We do not conduct studies that require subjects to stop taking their current medications.
- All site visits, tests, and medications are free of charge. This includes travel fees as we can arrange for travel accommodations. There is no insurance requirement and we will not ask for proof of insurance.
- Patients will need a study partner to attend patient visits to the office and help track the progress throughout the trial duration. Patients and study partners both have access to educational materials and resources in order to better understand Alzheimer's disease.
- Our office is a doctor's office. There are no guinea pigs nor will a patient ever be treated like one. Patients and study partners will be treated with dignity and care.
- Patients must satisfy several criteria which are determined via a phone screening with one of our staff and then a pre-screening process at our office. This pre-screening process may include, but not limit, an MRI and/or PET scan, standard tests of cognitive function and analysis of blood and urine chemistry at no cost to the patient.
- Being disqualified from a clinical trial can occur and can be related to a patient's other medical conditions or the medications currently being taken. Please do not lose hope or be discouraged! Even if a patient does not qualify for a study, we will still recommend the highest quality medical and educational resources available. Additionally, with the patients permission, we will contact them for future studies that they might qualify for.
- Informed consent must be obtained from the participant and study partner in order for the screening process to begin. Patients will know exactly what is expected of them before agreeing to participate. Patients may withdraw from the study at any point and/or any reason with no penalties. We will fully support the decision.
- Participating in a trial means patients will learn more about the trial affecting them and potentially receive a medication not available by prescription. Patients will be playing an active role in the development of a potentially disease altering medication.
- A patient may receive a placebo as part of the study. We do not know if the patient is on the placebo or actual drug. If a patient is on the placebo, and the drug proves effective, there may be an open label extension where the patient will receive the drug up until it is available by prescription.
- The treatment of memory loss is changing. Early diagnosis is clinically important and earlier interventions are being actively studied.
- We thoroughly understand the disease that is impacting a patient's life. While a patient may remain under the care of their current physician(s), we will treat patients with the highest level of empathy, dignity, and professionalism while under our supervision. Education is the cornerstone of the clinical trials process and the families that benefit most from this process are those needing answers and support. Patients will receive both at the Neuropsychiatric Research Center of Southwest Florida.
- The Neuropsychiatric Research Center of Southwest Florida is dedicated in finding effective treatments for those with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD). Early detection is as crucial a component for treating this disease as the treatments themselves. We are committed to bringing the best advancements in clinical research trials being conducted all over the world, and making them available to patients in Southwest Florida.
For more information please contact the
Neuropsychiatric Research Center of Southwest Florida